A phase I trial to evaluate the safety and immunogenicity of the HIV-1 pGA2/JS2 plasmid DNA vaccine [HIV DNA vaccine] given intramuscularly (IM) in HIV-1 uninfected adults
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2013
At a glance
- Drugs PGA2-JS2 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 26 Aug 2013 Planned End Date changed to 1 Apr 2003.
- 13 Nov 2008 Last checked against ClinicalTrials.gov record.
- 18 Jun 2007 Status changed from in progress to completed.